Distrobird — Free Sales Engagement Platform
Sequences, cloud call center, shared inbox, form tracking and more — on a single platform. Double your sales team's output with fewer tools.
Create a sequence — it's free
Qed Therapeutics
qed therapeutics, a subsidiary of bridgebio pharma, is a biotechnology company focused on precision medicine for fgfr-driven disorders. our lead candidate is infigratinib, a best-in-class fgfr kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with fgfr2 fusions. qed is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. we plan to develop infigratinib in additional fgfr-driven tumor types and rare disorders.
Frequently asked questions about Qed Therapeutics
Let us help answer the most common questions you might have.
Where is Qed Therapeutics located?
Qed Therapeutics' headquarters is located at 421 Kipling Street, Palo Alto, California, United States, 94301
What is Qed Therapeutics' official website?
Qed Therapeutics' official website is qedtx.com
How many employees does Qed Therapeutics have?
Qed Therapeutics has 44 employees
What industry does Qed Therapeutics belong to?
Qed Therapeutics is in the industry of: Biotechnology
What are Qed Therapeutics' social media links?
Qed Therapeutics Linkedin page
Distrobird — Free Sales Engagement Platform
Sequences, cloud call center, shared inbox, form tracking and more — on a single platform. Double your sales team's output with fewer tools.
Create a sequence — it's free